Kevin Alan Bryett

Seqirus Vaccines Ltd. manufactures vaccines. The company is headquartered in Maidenhead, the United Kingdom.

Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK

MSD Vaccines Ltd. manufactures and supplies vaccines. Its main way of achieving this goal is to develop and make available innovative vaccines against a wide spectrum of diseases. It also dedicated to increasing the understanding of the value of vaccines and vaccination by providing relevant and accurate information on their quality, safety and efficacy. The company was founded in 1975 and is headquartered in Maidenhead, the United Kingdom.

Delphic is a specialist laboratory company with world-leading capabilities in pharmacology and pharmacogenetics. It was the first company in the world to offer an integrated diagnostics and biomarker service in HIV and is now applying that model in hepatitis. It has particular expertise in infectious diseases, including capabilities in study design and in method development and transfer, and a growing clinical trials portfolio. It is planning to apply its expertise to other therapy areas. Delphic is growing, organically and by acquisition, into a specialist biomarker and companion diagnostics company able to support the growing demand for personalised medicine in clinical therapy and in drug development. Its laboratories are certified to ISO, GCLP, CAP and CLIA. It has global reach via its own laboratories in the UK and partner laboratories in Italy, Spain, Greece and Argentina.

Diurnal Group plc engages in the development of products for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia and adrenal insufficiency. It focuses on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena. The company was founded by Richard John Martin Ross in 2004 and is headquartered in Cardiff, the United Kingdom.